Related Experiment Videos
PROGNOSTIC VALUE OF PLASMA MYELOPEROXIDASE LEVEL'S AND ECHOCARDIOGRAPHIC DETERMINANTS IN CHRONIC HEART FAILURE
T Avaliani1, T Talakvadze1, S Tabagari1
1David Tvildiani Medical University, Tbilisi, Georgia.
Insights
Myeloperoxidase (MPO) levels are elevated in chronic heart failure (CHF) patients and correlate with disease severity and mortality risk. Increased MPO and right ventricular dysfunction predict worse outcomes in CHF patients.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Chronic heart failure (CHF) is a complex condition with significant morbidity and mortality.
- Identifying reliable biomarkers for predicting CHF progression and outcomes is crucial.
Purpose of the Study:
- To investigate Myeloperoxidase (MPO) levels in CHF patients across different severity stages.
- To determine the correlation of MPO with cardiac structural/functional markers and disease outcomes.
- To assess MPO's predictive value for mortality in CHF.
Main Methods:
- Eighty-six CHF patients and ten healthy controls were enrolled.
- MPO, hs-CRP, and leukocyte levels were measured using ELISA, turbidimetric immunoassay, and flow cytometry, respectively.
- Echocardiography assessed cardiac structure and function; 6-month follow-up evaluated mortality.
Main Results:
- MPO levels were significantly higher in CHF patients (9.3±7 ng/ml) compared to controls (4.19±2 ng/ml).
- Elevated MPO and hs-CRP levels were associated with increased mortality (p<0.007 and p<0.001, respectively).
- Increased right ventricle (RV) size and RVDD were linked to worse outcomes (p<0.005).
Conclusions:
- MPO is a potential biomarker for CHF severity and prognosis.
- MPO levels >7.1 ng/ml and increased RVDD independently predict worse outcomes in CHF patients.
- Further research into MPO's role in CHF pathogenesis and management is warranted.
Abstract:
The aim of current study was to investigate the level of Myeloperoxidase (MPO) in chronic heart failure patients with different severity and find the correlation with cardiac structural and functional markers and disease outcome. Initially eighty-six patients with different stages of CHF and ten healthy persons were included in our study. Excluded criteria were myocardial infarction or other concomitant acute diseases, renal failure (creatinine >250 µmol/L) in past 3 months. All patients underwent ECG, echocardiographic evaluation, anthropometric and other clinical examination, as well as plasma samples were collected for further analysis. MPO level (ng/ml) was measured by ELISA method, hs-CRP (mg/L) was measured by turbidimetric immunoassay and Leukocyte level (109/L) - by flow cytometry. Echocardiographic studies were performed using standard methods by parasternal and apical view. Statistical analyses were performed using IBM SPSS Statistics 16.0. After 6 month follow up we investigate our research primary outcome (mortality). The data were collected by telephone follow up from patients or members of family. Collection of information had been became possible in 79% of total cases (68 patients), from which 10 patients died: 8 cases were cardiovascular mortality, 1 case - suicide and 1 case from cancer. We found that MPO levels in the patients with CHF (mean value 9.3±7) are different from control group (mean value 4.19±2). MPO correlates with HF severity. MPO significantly were elevated in mortality group p<0,007 , as the level of hs-CRP p˂ 0.001. Changes of RV (right ventricule) sizes from normal ranges also were associated to worse outcome ( p<0.005). Depending on our data certain level of MPO (˃7.1 ng/ml) in studied patients and increased RVDD have independent importance for identification of patients with worse outcome.